Spectrum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SPPI)

$19.83 0.13 (0.66 %)
(As of 11/24/2017 06:25 AM ET)
Previous Close$19.70
Today's Range$19.50 - $19.97
52-Week Range$3.85 - $21.95
Volume298,234 shs
Average Volume1.17 million shs
Market Capitalization$1.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.65

About Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals logoSpectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Debt-to-Equity Ratio0.33%
Current Ratio5.04%
Quick Ratio4.89%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.44 million
Price / Sales13.63
Cash FlowN/A
Price / CashN/A
Book Value$3.03 per share
Price / Book6.54

Profitability

Trailing EPS($0.99)
Net Income$-68,510,000.00
Net Margins-58.94%
Return on Equity-29.73%
Return on Assets-16.45%

Miscellaneous

Employees227
Outstanding Shares100,660,000

Frequently Asked Questions for Spectrum Pharmaceuticals (NASDAQ:SPPI)

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.06. The biotechnology company had revenue of $36.40 million for the quarter, compared to the consensus estimate of $33.27 million. Spectrum Pharmaceuticals had a negative return on equity of 29.73% and a negative net margin of 58.94%. Spectrum Pharmaceuticals's revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.07) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

Where is Spectrum Pharmaceuticals' stock going? Where will Spectrum Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 12 month price objectives for Spectrum Pharmaceuticals' stock. Their forecasts range from $11.00 to $32.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $24.25 in the next twelve months. View Analyst Ratings for Spectrum Pharmaceuticals.

What are Wall Street analysts saying about Spectrum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Spectrum's low product sales remain a cause of concern. Moreover, gaining market share is challenging for Spectrum as it competes with several companies with greater financial strength. However, the company’s lead pipeline candidate, Rolontis, is progressing well. A BLA is expected in 2018 and a potential approval will help the company compete better. However, Spectrum’s efforts to gain approval for Qapzola (bladder cancer) in the U.S. suffered a setback with the FDA issuing a complete response letter (CRL) in Nov 2016. Additional issues on the regulatory/development front could affect the stock. Also, low product sales remain a cause of concern. On the flip side, with the company entering into out-licensing agreements for a number of products, it will now be able to focus on Evomela and the development of its pipeline candidates. Spectrum’s shares have significantly outperformed the industry so far this year." (10/4/2017)
  • 2. Jefferies Group LLC analysts commented, "SPPI is undervalued based on Rolontis' LT promise in chemotherapy-induced neutropenia. We see 50%+ share upside as Rolontis' Ph. III program is lower risk (with data in H1 2018) and we believe its profile, senior management's oncology experience, and CIN market dynamics should enable Rolontis to gain meaningful market share from Neulasta. Poziotinib in mBC/NSCLC bears watching and offers pipeline optionality. Assume at Buy and $7.50 PT." (2/10/2017)

Are investors shorting Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals saw a decline in short interest in the month of October. As of October 13th, there was short interest totalling 7,292,149 shares, a decline of 18.1% from the September 29th total of 8,909,100 shares. Based on an average daily trading volume, of 1,684,522 shares, the short-interest ratio is presently 4.3 days. Currently, 9.0% of the company's stock are sold short.

Who are some of Spectrum Pharmaceuticals' key competitors?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:

  • Rajesh C. Shrotriya M.D., Chairman of the Board, Chief Executive Officer (Age 73)
  • Joseph W. Turgeon, President, Chief Operating Officer (Age 59)
  • Kurt A. Gustafson, Chief Financial Officer, Executive Vice President (Age 49)
  • Luigi Lenaz M.D., Lead Independent Director (Age 76)
  • Gilles R. Gagnon, Director (Age 63)
  • Raymond Wayne Cohen, Independent Director (Age 58)
  • Stuart Mitchell Krassner, Independent Director (Age 81)
  • Anthony E. Maida III, Ph.D., Independent Director (Age 65)

Who owns Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include SHROTRIYA RAJESH C MD (8.89%), Dimensional Fund Advisors LP (2.53%), Macquarie Group Ltd. (1.47%), Wells Fargo & Company MN (0.94%), Bank of New York Mellon Corp (0.91%) and Principal Financial Group Inc. (0.75%). View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Who sold Spectrum Pharmaceuticals stock? Who is selling Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Macquarie Group Ltd., Dimensional Fund Advisors LP, Cornerstone Capital Management Holdings LLC., Granite Investment Partners LLC, California State Teachers Retirement System, State of Tennessee Treasury Department and Pinebridge Investments L.P.. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Who bought Spectrum Pharmaceuticals stock? Who is buying Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Wells Fargo & Company MN, Fisher Asset Management LLC, OxFORD Asset Management LLP, Schwab Charles Investment Management Inc., JPMorgan Chase & Co., ClariVest Asset Management LLC and Principal Financial Group Inc.. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy Spectrum Pharmaceuticals stock?

Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of Spectrum Pharmaceuticals stock can currently be purchased for approximately $19.83.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $1.98 billion and generates $146.44 million in revenue each year. The biotechnology company earns $-68,510,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Spectrum Pharmaceuticals employs 227 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (SPPI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Spectrum Pharmaceuticals (NASDAQ:SPPI)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.632.712.60
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.50$19.50$10.80$10.00
Price Target Upside: 1.40% upside3.17% upside15.38% upside65.84% upside

Consensus Price Target History for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Price Target History for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Analysts' Ratings History for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017HC WainwrightReiterated RatingBuyN/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$32.00N/AView Rating Details
10/20/2017Jefferies Group LLCBoost Price TargetBuy$25.00N/AView Rating Details
4/1/2017FBR & CoReiterated RatingBuyMediumView Rating Details
9/15/2016Royal Bank Of CanadaSet Price TargetBuy$11.00 -> $10.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Earnings by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Earnings History by Quarter for Spectrum Pharmaceuticals (NASDAQ SPPI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.16)($0.22)$33.27 million$36.40 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.27)($0.26)$30.50 million$34.30 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.20)($0.18)$32.23 million$29.10 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.27)($0.22)$31.13 million$35.24 millionViewListenView Earnings Details
11/14/2016Q3 2016($0.30)($0.22)$29.53 million$33.39 millionViewN/AView Earnings Details
8/9/2016Q216($0.29)($0.05)$30.88 million$33.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.14)$28.83 million$43.90 millionViewN/AView Earnings Details
3/9/2016Q415($0.18)($0.06)$33.87 million$50.30 millionViewN/AView Earnings Details
11/4/2015Q315($0.25)($0.28)$31.87 million$28.46 millionViewN/AView Earnings Details
8/6/2015Q215($0.22)($0.01)$34.48 million$44.98 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$48.00 million$38.60 millionViewN/AView Earnings Details
3/13/2015Q414($0.16)$0.09$48.50 million$51.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)$0.08$45.00 million$47.99 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)$0.09$41.50 million$46.90 millionViewListenView Earnings Details
5/8/2014Q114($0.22)$0.01$39.49 million$40.10 millionViewListenView Earnings Details
3/6/2014Q313($0.11)$0.05$41.96 million$41.50 millionViewListenView Earnings Details
11/12/2013Q3($0.07)($0.13)$38.70 million$42.44 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.12)($0.08)$33.41 million$33.23 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.32)($0.06)ViewN/AView Earnings Details
11/7/2012Q312$0.29$0.42$68.56 million$69.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Spectrum Pharmaceuticals (NASDAQ:SPPI)
2017 EPS Consensus Estimate: ($0.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.21)($0.21)($0.21)
Q2 20172($0.27)($0.23)($0.25)
Q3 20172($0.25)($0.19)($0.22)
Q4 20172($0.24)($0.22)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Spectrum Pharmaceuticals (NASDAQ SPPI)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$0.1512/18/201212/20/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Spectrum Pharmaceuticals (NASDAQ SPPI)

Insider Ownership Percentage: 13.33%
Institutional Ownership Percentage: 58.45%
Insider Trades by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Insider Trades by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Insider Trades by Quarter for Spectrum Pharmaceuticals (NASDAQ SPPI)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/5/2013Anthony E Maida IIIDirectorSell5,000$12.25$61,250.00View SEC Filing  
11/12/2012Joseph Kenneth KellerCOOBuy10,000$10.95$109,500.00View SEC Filing  
11/1/2012Anthony E Maida IIIDirectorSell5,000$11.09$55,450.00View SEC Filing  
9/4/2012Anthony E Maida IIIDirectorSell5,000$12.01$60,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Spectrum Pharmaceuticals (NASDAQ SPPI)

Source:
DateHeadline
Financial Survey: Spectrum Pharmaceuticals (SPPI) versus Its CompetitorsFinancial Survey: Spectrum Pharmaceuticals (SPPI) versus Its Competitors
www.americanbankingnews.com - November 20 at 1:30 AM
Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Myriad GeneticsToday’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Myriad Genetics
finance.yahoo.com - November 18 at 8:57 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $33.05 MillionSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $33.05 Million
www.americanbankingnews.com - November 17 at 10:26 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Earnings of -$0.25 Per ShareSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - November 15 at 11:41 AM
Why Spectrum Pharmaceuticals Stock Soared in OctoberWhy Spectrum Pharmaceuticals Stock Soared in October
www.fool.com - November 8 at 12:19 PM
Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates - NasdaqSpectrum (SPPI) Earnings, Sales Beat Q3 Estimates - Nasdaq
www.nasdaq.com - November 5 at 2:41 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Stock Rating Reaffirmed by HC WainwrightSpectrum Pharmaceuticals, Inc. (SPPI) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 4 at 11:32 PM
Spectrum Pharmaceuticals, Inc. to Host Earnings CallSpectrum Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 4:39 PM
Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline UpdateSpectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update
finance.yahoo.com - November 4 at 4:39 PM
Spectrum Pharma reports 3Q lossSpectrum Pharma reports 3Q loss
finance.yahoo.com - November 4 at 4:38 PM
Edited Transcript of SPPI earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of SPPI earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 4:38 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Issues  Earnings ResultsSpectrum Pharmaceuticals, Inc. (SPPI) Issues Earnings Results
www.americanbankingnews.com - November 3 at 4:02 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Receives Average Recommendation of "Buy" from AnalystsSpectrum Pharmaceuticals, Inc. (SPPI) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 2 at 9:44 PM
Spectrum Pharmaceuticals (SPPI) Q3 Earnings: Whats in Store?Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?
www.zacks.com - November 2 at 9:06 AM
Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and WebcastSpectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and Webcast
finance.yahoo.com - October 28 at 6:55 AM
Short Interest in Spectrum Pharmaceuticals, Inc. (SPPI) Decreases By 18.1%Short Interest in Spectrum Pharmaceuticals, Inc. (SPPI) Decreases By 18.1%
www.americanbankingnews.com - October 27 at 1:40 AM
Zacks: Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Announce Earnings of -$0.23 Per ShareZacks: Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - October 25 at 11:30 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Now Covered by Analysts at GuggenheimSpectrum Pharmaceuticals, Inc. (SPPI) Now Covered by Analysts at Guggenheim
www.americanbankingnews.com - October 23 at 6:50 PM
Critical Survey: Spectrum Pharmaceuticals (SPPI) vs. Its PeersCritical Survey: Spectrum Pharmaceuticals (SPPI) vs. Its Peers
www.americanbankingnews.com - October 22 at 8:20 AM
Jefferies Group LLC Raises Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $25.00Jefferies Group LLC Raises Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $25.00
www.americanbankingnews.com - October 21 at 2:58 PM
Spectrum Pharmaceuticals Inc. (SPPI) Leaped To A New High On Phase 2 Study NewsSpectrum Pharmaceuticals Inc. (SPPI) Leaped To A New High On Phase 2 Study News
www.rttnews.com - October 20 at 8:22 AM
Spectrum Pharmaceuticals Inc. (SPPI) Has Surged To A New High On Study Results - NasdaqSpectrum Pharmaceuticals Inc. (SPPI) Has Surged To A New High On Study Results - Nasdaq
www.nasdaq.com - October 19 at 9:10 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Receives Buy Rating from HC WainwrightSpectrum Pharmaceuticals, Inc. (SPPI) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - October 18 at 7:08 PM
Jefferies Group Weighs in on Spectrum Pharmaceuticals, Inc.s Q3 2017 Earnings (SPPI)Jefferies Group Weighs in on Spectrum Pharmaceuticals, Inc.'s Q3 2017 Earnings (SPPI)
www.americanbankingnews.com - October 11 at 6:08 AM
Jefferies Group LLC Boosts Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $18.00Jefferies Group LLC Boosts Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $18.00
www.americanbankingnews.com - October 9 at 10:38 AM
HC Wainwright Boosts Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $20.00HC Wainwright Boosts Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $20.00
www.americanbankingnews.com - October 9 at 12:28 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Downgraded to "Sell" at Zacks Investment ResearchSpectrum Pharmaceuticals, Inc. (SPPI) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - October 8 at 6:40 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by AnalystsSpectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 8 at 6:38 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $34.40 MillionSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $34.40 Million
www.americanbankingnews.com - October 8 at 1:02 AM
-$0.22 Earnings Per Share Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter-$0.22 Earnings Per Share Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter
www.americanbankingnews.com - October 7 at 12:18 AM
BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facilityBRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility
www.reuters.com - September 30 at 11:24 AM
Spectrum Pharma (SPPI) Says it Issued Approximately 9.3M Shares of Common Stock Under Previously Announced At-The-Market FacilitySpectrum Pharma (SPPI) Says it Issued Approximately 9.3M Shares of Common Stock Under Previously Announced At-The-Market Facility
www.streetinsider.com - September 30 at 11:24 AM
Spectrum Pharmaceuticals Provides Update On At-The-Market FacilitySpectrum Pharmaceuticals Provides Update On At-The-Market Facility
www.thestreet.com - September 30 at 11:24 AM
Spectrum Pharma (SPPI) Says Poziotinib Data in Lung Cancer to be Presented at IASLC - StreetInsider.comSpectrum Pharma (SPPI) Says Poziotinib Data in Lung Cancer to be Presented at IASLC - StreetInsider.com
www.streetinsider.com - September 29 at 7:02 AM
Q3 2017 Earnings Estimate for Spectrum Pharmaceuticals, Inc. Issued By Jefferies Group (SPPI)Q3 2017 Earnings Estimate for Spectrum Pharmaceuticals, Inc. Issued By Jefferies Group (SPPI)
www.americanbankingnews.com - September 27 at 8:00 AM
Jefferies Group Research Analysts Reduce Earnings Estimates for Spectrum Pharmaceuticals, Inc. (SPPI)Jefferies Group Research Analysts Reduce Earnings Estimates for Spectrum Pharmaceuticals, Inc. (SPPI)
www.americanbankingnews.com - September 26 at 3:24 PM
Reviewing Compugen (CGEN) and Spectrum Pharmaceuticals (SPPI)Reviewing Compugen (CGEN) and Spectrum Pharmaceuticals (SPPI)
www.americanbankingnews.com - September 17 at 10:32 PM
HC Wainwright Reiterates "Buy" Rating for Spectrum Pharmaceuticals, Inc. (SPPI)HC Wainwright Reiterates "Buy" Rating for Spectrum Pharmaceuticals, Inc. (SPPI)
www.americanbankingnews.com - September 14 at 4:18 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Receives Average Rating of "Buy" from BrokeragesSpectrum Pharmaceuticals, Inc. (SPPI) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 13 at 8:54 PM
Comparing Spectrum Pharmaceuticals (SPPI) and Portola Pharmaceuticals (PTLA)Comparing Spectrum Pharmaceuticals (SPPI) and Portola Pharmaceuticals (PTLA)
www.americanbankingnews.com - September 10 at 3:02 PM
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September - Business Wire (press release)Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September - Business Wire (press release)
www.businesswire.com - September 5 at 9:40 PM
Advaxis (ADXS) & Spectrum Pharmaceuticals (SPPI) Critical ReviewAdvaxis (ADXS) & Spectrum Pharmaceuticals (SPPI) Critical Review
www.americanbankingnews.com - September 5 at 6:04 PM
 Brokerages Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Announce Quarterly Sales of $34.40 Million Brokerages Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Announce Quarterly Sales of $34.40 Million
www.americanbankingnews.com - September 1 at 3:26 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Post Earnings of -$0.23 Per ShareSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - August 30 at 6:16 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Given a $9.00 Price Target at Jefferies Group LLCSpectrum Pharmaceuticals, Inc. (SPPI) Given a $9.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - August 26 at 8:16 AM
HC Wainwright Reiterates Buy Rating for Spectrum Pharmaceuticals, Inc. (SPPI)HC Wainwright Reiterates Buy Rating for Spectrum Pharmaceuticals, Inc. (SPPI)
www.americanbankingnews.com - August 21 at 12:34 AM
Spectrum Pharma (SPPI) Reports Initiation of Registrational Phase 3 Trial of Qapzola in Patients with Non-Muscle ... - StreetInsider.comSpectrum Pharma (SPPI) Reports Initiation of Registrational Phase 3 Trial of Qapzola in Patients with Non-Muscle ... - StreetInsider.com
www.streetinsider.com - August 15 at 7:12 AM
Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
finance.yahoo.com - August 15 at 7:12 AM
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Expected to Announce Quarterly Sales of $29.86 MillionSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Expected to Announce Quarterly Sales of $29.86 Million
www.americanbankingnews.com - August 14 at 9:52 AM
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Posts Quarterly  Earnings Results, Beats Estimates By $0.01 EPSSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 5 at 12:46 AM

Social Media

Financials

Chart

Spectrum Pharmaceuticals (NASDAQ SPPI) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.